10 CMS and FDA Actions Affecting Care in 2026 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

  • By

  • mdspire news news staff

  • July 10, 2026

  • 7 min

Share

  • 1

    The 2026 Medicare Physician Fee Schedule final rule establishes separate conversion factors for qualifying and nonqualifying alternative payment model participants.

  • 2

    The 2026 Medicare Advantage and Part D final rule implements changes to prescription drug coverage and eliminates cost-sharing for certain adult vaccines.

  • 3

    CMS finalized a 2.6% update to payment rates for hospital outpatient services and ambulatory surgical centers meeting quality reporting requirements.

  • 4

    The FDA approved Foundayo, an oral GLP-1 therapy, for weight management in adults with obesity or overweight and related comorbid conditions.

  • 5

    The FDA cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use by children aged 2 years and older who do not use insulin.

Original Source(s)

10 CMS and FDA Actions Affecting Care in 2026

  • by mdspire news news staff

  • July 10, 2026

Related Content

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.

Medical Trauma on the Inpatient Medicine Service: Perspectives of Recently Hospitalized Patients, Residents, and the Interdisciplinary Care Team

Case Report Describes Possible Betahistine–Suicidality Link

A single case report described suicidal ideation that resolved after betahistine discontinuation and recurred after rechallenge, but the findings cannot establish causality or quantify risk.